EYPT - Company ID 0001314102
EyePoint Pharmaceuticals, Inc. trades as EYPT and has a market capitalization of $1.21 B, making it the #2513 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $31.37M, down 27.5% from the prior year and net income of -$231.96M. This page tracks EyePoint Pharmaceuticals, Inc. through 1,308 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-10
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years EyePoint Pharmaceuticals, Inc.'s revenue grew from $1.62M to $31.37M, a compound annual growth rate of 39.0%. Net profit margin expanded from -1330.1% to -739.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| Major company event | 8-K | 2026-05-14 |
| SCHEDULE 13G/A | - | 2026-05-13 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-06 |
| Proxy materials | DEFA14A | 2026-04-27 |
| Proxy statement | DEF 14A | 2026-04-27 |
| Insider trade | 4 | 2026-04-20 |
The largest companies sharing EyePoint Pharmaceuticals, Inc.'s SEC industry classification (laboratory analytical instruments).
EyePoint Pharmaceuticals, Inc. (EYPT) has a market capitalization of $1.21 B as of 2026-07-10, ranking #2513 among US-listed companies.
EyePoint Pharmaceuticals, Inc. reported revenue of $31.37M for fiscal year 2025, a decrease of 27.5% year over year.
In its latest fiscal year EyePoint Pharmaceuticals, Inc. reported a net loss of $231.96M.